Telomir Pharmaceuticals Receives FDA Clearance for Phase 1/2 Trial of Telomir-Zn in Triple-Negative Breast Cancer

The U.S. Food and Drug Administration has cleared an Investigational New Drug application from Telomir Pharmaceuticals (NASDAQ: TELO) for its lead candidate, Telomir-Zn, to treat advanced or metastatic triple-negative breast cancer. The clearance allows the company to initiate a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing and preliminary antitumor activity.

Telomir Pharmaceuticals, a clinical-stage biotechnology company, announced the milestone, which is supported by preclinical pharmacology, toxicology and biomarker data. The company is advancing its lead candidate toward clinical development, with the trial expected to provide critical insights into the drug’s potential in a difficult-to-treat cancer type. Triple-negative breast cancer is an aggressive form of breast cancer that lacks targeted treatment options, making new therapies particularly important.

The announcement highlights the company’s focus on small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Telomir-Zn, also known as Telomir-1, has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.

Investors and industry observers can find the latest news and updates relating to TELO in the company’s newsroom at https://ibn.fm/TELO. The full press release is available at https://ibn.fm/p4e9J.

The FDA clearance represents a significant regulatory step for Telomir Pharmaceuticals as it transitions from preclinical to clinical development. The Phase 1/2 trial will be closely watched for signs of safety and efficacy in a patient population with high unmet medical need. If successful, Telomir-Zn could offer a new treatment avenue for triple-negative breast cancer, potentially improving outcomes for patients who currently have limited options.

Telomir Pharmaceuticals is headquartered in the United States and focuses on developing therapies that address the underlying mechanisms of disease. The company’s approach targets epigenetic and metabolic pathways, which are increasingly recognized as key drivers of cancer and aging-related conditions. The IND clearance for Telomir-Zn underscores the potential of this strategy and sets the stage for clinical evaluation.

As the company moves forward with the trial, stakeholders will be monitoring enrollment, safety data, and early signs of antitumor activity. The outcome could have implications not only for triple-negative breast cancer but also for other indications where Telomir-Zn’s mechanism of action may be relevant.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Telomir Pharmaceuticals Receives FDA Clearance for Phase 1/2 Trial of Telomir-Zn in Triple-Negative Breast Cancer.

The post Telomir Pharmaceuticals Receives FDA Clearance for Phase 1/2 Trial of Telomir-Zn in Triple-Negative Breast Cancer appeared first on citybuzz.